Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019

Endoscopy

Volumn 51, Issue 4, 2019, Pages 365-388

  Pimentel Nunes, Pedro ^a,b   Libânio, Diogo ^a,b   Marcos Pinto, Ricardo ^b,c   Areia, Miguel ^b,d   Leja, Marcis ^e   Esposito, Gianluca ^f   Garrido, Monica ^c   Kikuste, Ilze ^e   Megraud, Francis ^g   Matysiak Budnik, Tamara ^h   Annibale, Bruno ^f   Dumonceau, Jean Marc ⁱ   Barros, Rita ^j,k   Fléjou, Jean François ^l   Carneiro, Fátima ^j,k,m   Van Hooft, Jeanin E ⁿ   Kuipers, Ernst J ^o   Dinis Ribeiro, Mario ^a,b  

^a PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^b University of Porto   (Portugal)

^c Institute of Biomedical Sciences Abel Salazar   (Portugal)

^d Instituto Portugues de Oncologia Francisco Gentil Centro Regional de Oncologia de Coimbra SA   (Portugal)

^e UNIVERSITY OF LATVIA   (Latvia)

^f SAPIENZA UNIVERSITY OF ROME   (Italy)

^g UNIVERSITÉ DE BORDEAUX   (France)

^h NANTES UNIVERSITY HOSPITAL   (France)

ⁱ Diagnostic and Therapeutic Gastroenterology and Endoscopy   (Argentina)

^j UNIVERSITY OF PORTO   (Portugal)

^k UNIVERSITY OF PORTO   (Portugal)

^l HÔPITAL SAINT ANTOINE   (France)

^m Universidade do Porto   (Portugal)

ⁿ UNIVERSITY OF AMSTERDAM   (Netherlands)

^o ERASMUS MEDICAL CENTER   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; HERBACEOUS AGENT; MOLUODAN; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR; REBAMIPIDE; UNCLASSIFIED DRUG; VITAMIN;

ARTICLE; ATROPHIC GASTRITIS; AUTOIMMUNE DISEASE; CANCER SCREENING; CANCER STAGING; COST EFFECTIVENESS ANALYSIS; DISEASE SURVEILLANCE; DYSPLASIA; EARLY CANCER; ERADICATION THERAPY; GASTRITIS; GASTROSCOPY; HELICOBACTER INFECTION; HUMAN; INTESTINE METAPLASIA; NON INVASIVE MEASUREMENT; PRACTICE GUIDELINE; PRECANCER; PRIORITY JOURNAL; RISK FACTOR; STOMACH BIOPSY; STOMACH CARCINOGENESIS; STOMACH EPITHELIUM; STOMACH LESION; BIOPSY; EUROPE; GASTROINTESTINAL ENDOSCOPY; METAPLASIA; PATHOLOGY; PATIENT CARE; PROCEDURES; RISK ASSESSMENT; STOMACH TUMOR;

BIOPSY; ENDOSCOPY, GASTROINTESTINAL; EUROPE; GASTRITIS, ATROPHIC; HELICOBACTER INFECTIONS; HUMANS; METAPLASIA; PATIENT CARE MANAGEMENT; PRECANCEROUS CONDITIONS; RISK ASSESSMENT; STOMACH NEOPLASMS;

EID: 85063187030     PISSN: 0013726X     EISSN: 14388812     Source Type: Journal    
DOI: 10.1055/a-0859-1883     Document Type: Article

References (191)

1. Bray F. Ferlay J. Soerjomataram I. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin: 2018; 68 393 424
2. Pimentel-Nunes P. Dinis-Ribeiro M. Endoscopic submucosal dissection in the treatment of gastrointestinal superficial lesions: Follow the guidelines! GE Port J Gastroenterol: 2015; 22 184 186
3. Pimentel-Nunes P. Dinis-Ribeiro M. Ponchon T. et al. Endoscopic submucosal dissection: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy: 2015; 47 829 854
4. Dinis-Ribeiro M. Areia M. de Vries A. C. et al. Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED). Endoscopy: 2012; 44 74 94
5. Dinis-Ribeiro M. Areia M. de Vries A. C. et al. Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED). Virchows Arch: 2012; 460 19 46
6. Bisschops R. Areia M. Coron E. et al. Performance measures for upper gastrointestinal endoscopy: a European Society of Gastrointestinal Endoscopy (ESGE) Quality Improvement Initiative. Endoscopy: 2016; 48 843 864
7. AGREE Collaboration Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE project. Qual Saf Health Care: 2003; 12 18 23
8. Atkins D. Eccles M. Flottorp S. et al. Systems for grading the quality of evidence and the strength of recommendations I: critical appraisal of existing approaches The GRADE Working Group. BMC Health Serv Res: 2004; 4 38
9. Guyatt G. H. Oxman A. D. Vist G. E. et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ: 2008; 336 924 926
10. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process - First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res: 1992; 52 6735 6740
11. Kapadia C. R. Gastric atrophy, metaplasia and dysplasia: a clinical perspective. J Clin Gastroenterol: 2003; 36 S29 36
12. Carneiro F. Machado J. C. David L. et al. Current thoughts on the histopathogenesis of gastric cancer. Eur J Cancer Prev: 2001; 10 101 102
13. Ihamaki T. Sankkonen M. Siurala M. Long-term observation of subjects with normal mucosa and with superficial gastritis: results of 23â-â27 years' follow-up examinations. Scand J Gastroenterol: 1978; 13 771 775
14. Ormiston M. C. Gear M. W. Codling B. W. Five year follow-up study of gastritis. J Clin Pathol: 1982; 35 757 760
15. Laurèn P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. Acta Pathol Microbiol Scand: 1965; 64 31 49
16. Fukao A. Hisamichi S. Ohsato N. et al. Correlation between the prevalence of gastritis and gastric cancer in Japan. Cancer Causes Control: 1993; 4 17.20
17. Genta R. M. Gastric atrophy and atrophic gastritis - nebulous concepts in search of a definition. Aliment Pharmacol Ther: 1998; 12 17 23
18. Yue H. Shan L. Bin L. The significance of OLGA and OLGIM staging systems in the risk assessment of gastric cancer: a systematic review and meta-analysis. Gastric Cancer: 2018; 21 579 587, Epub 2018 Feb 19
19. Mera R. M. Bravo L. E. Camargo M. C. et al. Dynamics of Helicobacter pylori infection as a determinant of progression of gastric precancerous lesions: 16-year follow-up of an eradication trial. Gut: 2018; 67 1239 1246, Epub 2017 Jun 24
20. Dixon M. F. Genta R. M. Yardley J. H. et al. Classification and grading of gastritis. The updated Sydney System. International workshop on the histopathology of gastritis, Houston 1994. Am J Surg Pathol: 1996; 20 1161 1181
21. Misiewicz J. J. The Sydney System: a new classification of gastritis. Introduction. J Gastroenterol Hepatol: 1991; 6 207 208
22. Plummer M. Buiatti E. Lopez G. et al. Histological diagnosis of precancerous lesions of the stomach: a reliability study. Int J Epidemiol: 1997; 26 716 720
23. Cotruta B. Gheorghe C. Iacob R. et al. The orientation of gastric biopsy samples improves the inter-observer agreement of the OLGA staging system. J Gastrointestin Liver Dis: 2017; 26 351 356
24. Isajevs S. Liepniece-Karele I. Janciauskas D. et al. Gastritis staging: interobserver agreement by applying OLGA and OLGIM systems. Virchows Arch: 2014; 464 403 407
25. Correa P. Clinical implications of recent developments in gastric cancer pathology and epidemiology. Semin Oncol: 1985; 12 2 10
26. Lauwers G. Carneiro F. Graham D. et al. Gastric carcinoma. In: Theise N., ed. WHO Classification of tumours of the digestive system. Lyon IARC Press: 2010; 48 58
27. Lim H. Jung H. Y. Park Y. S. et al. Discrepancy between endoscopic forceps biopsy and endoscopic resection in gastric epithelial neoplasia. Surg Endosc: 2014; 28 1256 1262
28. Pimentel-Nunes P. Mourao F. Veloso N. et al. Long-term follow-up after endoscopic resection of gastric superficial neoplastic lesions in Portugal. Endoscopy: 2014; 46 933 940
29. Zhao G. Xue M. Hu Y. et al. How commonly is the diagnosis of gastric low grade dysplasia upgraded following endoscopic resection? A meta-analysis. PLoS One: 2015; 10 e0132699
30. Atkins L. Benedict E. B. Correlation of gross gastroscopic findings with gastroscopic biopsy in gastritis. N Engl J Med: 1956; 254 641 644
31. Carpenter H. A. Talley N. J. Gastroscopy is incomplete without biopsy: clinical relevance of distinguishing gastropathy from gastritis. Gastroenterology: 1995; 108 917 924
32. Eshmuratov A. Nah J. C. Kim N. et al. The correlation of endoscopic and histological diagnosis of gastric atrophy. Dig Dis Sci: 2010; 55 1364 1375
33. Redéen S. Petersson F. Jönsson K. A. et al. Relationship of gastroscopic features to histological findings in gastritis and Helicobacter pylori infection in a general population sample. Endoscopy: 2003; 35 946 950
34. Stathopoulos G. Goldberg R. D. Blackstone M. O. Endoscopic diagnosis of intestinal metaplasia. Gastrointest Endosc: 1990; 36 544 545
35. Panteris V. Nikolopoulou S. Lountou A. et al. Diagnostic capabilities of high-definition white light endoscopy for the diagnosis of gastric intestinal metaplasia and correlation with histologic and clinical data. Eur J Gastroenterol Hepatol: 2014; 26 594 601
36. Pimentel-Nunes P. Libanio D. Lage J. et al. A multicenter prospective study of the real-time use of narrow-band imaging in the diagnosis of premalignant gastric conditions and lesions. Endoscopy: 2016; 48 723 730
37. Ang T. L. Pittayanon R. Lau J. Y. et al. A multicenter randomized comparison between high-definition white light endoscopy and narrow band imaging for detection of gastric lesions. Eur J Gastroenterol Hepatol: 2015; 27 1473 1478
38. Anagnostopoulos G. K. Yao K. Kaye P. et al. High-resolution magnification endoscopy can reliably identify normal gastric mucosa, Helicobacter pylori-associated gastritis, and gastric atrophy. Endoscopy: 2007; 39 202 207
39. Gonen C. Simsek I. Sarioglu S. et al. Comparison of high resolution magnifying endoscopy and standard videoendoscopy for the diagnosis of Helicobacter pylori gastritis in routine clinical practice: a prospective study. Helicobacter: 2009; 14 12 21
40. Tahara T. Shibata T. Nakamura M. et al. Gastric mucosal pattern by using magnifying narrow-band imaging endoscopy clearly distinguishes histological and serological severity of chronic gastritis. Gastrointest Endosc: 2009; 70 246 253
41. Areia M. Amaro P. Dinis-Ribeiro M. et al. External validation of a classification for methylene blue magnification chromoendoscopy in premalignant gastric lesions. Gastrointest Endosc: 2008; 67 1011 1018
42. Dinis-Ribeiro M. da Costa-Pereira A. Lopes C. et al. Magnification chromoendoscopy for the diagnosis of gastric intestinal metaplasia and dysplasia. Gastrointest Endosc: 2003; 57 498 504
43. Kono Y. Takenaka R. Kawahara Y. et al. Chromoendoscopy of gastric adenoma using an acetic acid indigocarmine mixture. World J Gastroenterol: 2014; 20 5092 5097
44. Mouzyka S. Fedoseeva A. Chromoendoscopy with hematoxylin in the classification of gastric lesions. Gastric Cancer: 2008; 11 15 21; discussion 21-12
45. Tanaka K. Toyoda H. Kadowaki S. et al. Surface pattern classification by enhanced-magnification endoscopy for identifying early gastric cancers. Gastrointest Endosc: 2008; 67 430 437
46. Zhao Z. Yin Z. Wang S. et al. Meta-analysis: The diagnostic efficacy of chromoendoscopy for early gastric cancer and premalignant gastric lesions. J Gastroenterol Hepatol: 2016; 31 1539 1545
47. Kikuste I. Marques-Pereira R. Monteiro-Soares M. et al. Systematic review of the diagnosis of gastric premalignant conditions and neoplasia with high-resolution endoscopic technologies. Scand J Gastroenterol: 2013; 48 1108 1117
48. Pimentel-Nunes P. Dinis-Ribeiro M. Soares J. B. et al. A multicenter validation of an endoscopic classification with narrow band imaging for gastric precancerous and cancerous lesions. Endoscopy: 2012; 44 236 246
49. Dias-Silva D. Pimentel-Nunes P. Magalhaes J. et al. The learning curve for narrow-band imaging in the diagnosis of precancerous gastric lesions by using web-based video. Gastrointest Endosc: 2014; 79 910 920; quiz 983-e911, 983 e914
50. East J. E. Vleugels J. L. Roelandt P. et al. Advanced endoscopic imaging: European Society of Gastrointestinal Endoscopy (ESGE) Technology Review. Endoscopy: 2016; 48 1029 1045
51. Dutta A. K. Sajith K. G. Pulimood A. B. et al. Narrow band imaging versus white light gastroscopy in detecting potentially premalignant gastric lesions: a randomized prospective crossover study. Indian J Gastroenterol: 2013; 32 37 42
52. Xirouchakis E. Laoudi F. Tsartsali L. et al. Screening for gastric premalignant lesions with narrow band imaging, white light and updated Sydney protocol or both? Dig Dis Sci: 2013; 58 1084 1090
53. Buxbaum J. L. Hormozdi D. Dinis-Ribeiro M. et al. Narrow-band imaging versus white light versus mapping biopsy for gastric intestinal metaplasia: a prospective blinded trial. Gastrointest Endosc: 2017; 86 857 865
54. Lage J. Pimentel-Nunes P. Figueiredo P. C. et al. Light-NBI to identify high-risk phenotypes for gastric adenocarcinoma: do we still need biopsies? Scand J Gastroenterol: 2016; 51 501 506
55. Ezoe Y. Muto M. Uedo N. et al. Magnifying narrowband imaging is more accurate than conventional white-light imaging in diagnosis of gastric mucosal cancer. Gastroenterology: 2011; 141 2017 2025 e2013
56. Zhang Q. Wang F. Chen Z. Y. et al. Comparison of the diagnostic efficacy of white light endoscopy and magnifying endoscopy with narrow band imaging for early gastric cancer: a meta-analysis. Gastric Cancer: 2016; 19 543 552
57. Pimenta-Melo A. R. Monteiro-Soares M. Libanio D. et al. Missing rate for gastric cancer during upper gastrointestinal endoscopy: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol: 2016; 28 1041 1049
58. Pimentel-Nunes P. Libanio D. Dinis-Ribeiro M. Evaluation and management of gastric superficial neoplastic lesions. GE Port J Gastroenterol: 2017; 24 8 21
59. Lee J. W. Lim L. G. Yeoh K. G. Advanced endoscopic imaging in gastric neoplasia and preneoplasia. BMJ Open Gastroenterol: 2017; 4 e000105
60. Dohi O. Yagi N. Majima A. et al. Diagnostic ability of magnifying endoscopy with blue laser imaging for early gastric cancer: a prospective study. Gastric Cancer: 2017; 20 297 303
61. Dohi O. Yagi N. Yoshida S. et al. Magnifying blue laser imaging versus magnifying narrow-band imaging for the diagnosis of early gastric cancer: a prospective, multicenter, comparative study. Digestion: 2017; 96 127 134
62. Kaneko K. Oono Y. Yano T. et al. Effect of novel bright image enhanced endoscopy using blue laser imaging (BLI). Endosc Int Open: 2014; 2 E212 219
63. Mao X. Y. Xu S. F. Liu Q. et al. Anatomical predilection of intestinal metaplasia based on 78,335 endoscopic cases. Saudi J Gastroenterol: 2016; 22 154 160
64. Kim Y. I. Kook M. C. Cho S. J. et al. Effect of biopsy site on detection of gastric cancer high-risk groups by OLGA and OLGIM stages. Helicobacter: 2017; 10.1111/hel.12442
65. Isajevs S. Liepniece-Karele I. Janciauskas D. et al. The effect of incisura angularis biopsy sampling on the assessment of gastritis stage. Eur J Gastroenterol Hepatol: 2014; 26 510 513
66. Lash J. G. Genta R. M. Adherence to the Sydney System guidelines increases the detection of Helicobacter gastritis and intestinal metaplasia in 400738 sets of gastric biopsies. Aliment Pharmacol Ther: 2013; 38 424 431
67. Varbanova M. Wex T. Jechorek D. et al. Impact of the angulus biopsy for the detection of gastric preneoplastic conditions and gastric cancer risk assessment. J Clin Pathol: 2016; 69 19 25
68. Marcos-Pinto R. Carneiro F. Dinis-Ribeiro M. et al. First-degree relatives of patients with early-onset gastric carcinoma show even at young ages a high prevalence of advanced OLGA/OLGIM stages and dysplasia. Aliment Pharmacol Ther: 2012; 35 1451 1459
69. Rugge M. Meggio A. Pennelli G. et al. Gastritis staging in clinical practice: the OLGA staging system. Gut: 2007; 56 631 636
70. Rugge M. de Boni M. Pennelli G. et al. Gastritis OLGA-staging and gastric cancer risk: a twelve-year clinico-pathological follow-up study. Aliment Pharmacol Ther: 2010; 31 1104 1111
71. Capelle L. G. de Vries A. C. Haringsma J. et al. The staging of gastritis with the OLGA system by using intestinal metaplasia as an accurate alternative for atrophic gastritis. Gastrointest Endosc: 2010; 71 1150 1158
72. Dinis-Ribeiro M. Yamaki G. Miki K. et al. Meta-analysis on the validity of pepsinogen test for gastric carcinoma, dysplasia or chronic atrophic gastritis screening. J Med Screen: 2004; 11 141 147
73. Cho J. H. Jeon S. R. Kim H. G. et al. The serum pepsinogen levels for risk assessment of gastric neoplasms: New proposal from a case-control study in Korea. Medicine (Baltimore): 2017; 96 e7603
74. Tong Y. Wu Y. Song Z. et al. The potential value of serum pepsinogen for the diagnosis of atrophic gastritis among the health check-up populations in China: a diagnostic clinical research. BMC Gastroenterol: 2017; 17 88
75. Huang Y. K. Yu J. C. Kang W. M. et al. Significance of serum pepsinogens as a biomarker for gastric cancer and atrophic gastritis screening: a systematic review and meta-analysis. PLoS One: 2015; 10 e0142080
76. Kitahara F. Kobayashi K. Sato T. et al. Accuracy of screening for gastric cancer using serum pepsinogen concentrations. Gut: 1999; 44 693 697
77. Leja M. Camargo M. C. Polaka I. et al. Detection of gastric atrophy by circulating pepsinogens: A comparison of three assays. Helicobacter: 2017; 10.1111/hel.12393
78. Zagari R. M. Rabitti S. Greenwood D. C. et al. Systematic review with meta-analysis: diagnostic performance of the combination of pepsinogen, gastrin-17 and anti-Helicobacter pylori antibodies serum assays for the diagnosis of atrophic gastritis. Aliment Pharmacol Ther: 2017; 46 657 667
79. Leja M. Kupcinskas L. Funka K. et al. Value of gastrin-17 in detecting antral atrophy. Adv Med Sci: 2011; 56 145 150
80. Watabe H. Mitsushima T. Yamaji Y. et al. Predicting the development of gastric cancer from combining Helicobacter pylori antibodies and serum pepsinogen status: a prospective endoscopic cohort study. Gut: 2005; 54 764 768
81. Yoshida T. Kato J. Inoue I. et al. Cancer development based on chronic active gastritis and resulting gastric atrophy as assessed by serum levels of pepsinogen and Helicobacter pylori antibody titer. Int J Cancer: 2014; 134 1445 1457
82. Kawashima J. Ohno S. Sakurada T. et al. Circulating acylated ghrelin level decreases in accordance with the extent of atrophic gastritis. J Gastroenterol: 2009; 44 1046 1054
83. Eun Bae S. Hoon Lee J. Soo Park Y. et al. Decrease of serum total ghrelin in extensive atrophic gastritis: comparison with pepsinogens in histological reference. Scand J Gastroenterol: 2016; 51 137 144
84. Kasai C. Sugimoto K. Moritani I. et al. Changes in plasma ghrelin and leptin levels in patients with peptic ulcer and gastritis following eradication of Helicobacter pylori infection. BMC Gastroenterol: 2016; 16 119
85. Shi S. Q. Cai J. T. Yang J. M. Expression of trefoil factors 1 and 2 in precancerous condition and gastric cancer. World J Gastroenterol: 2006; 12 3119 3122
86. Link A. Schirrmeister W. Langner C. et al. Differential expression of microRNAs in preneoplastic gastric mucosa. Scientific reports: 2015; 5 8270
87. Amal H. Leja M. Funka K. et al. Detection of precancerous gastric lesions and gastric cancer through exhaled breath. Gut: 2016; 65 400 407
88. [Anonymous] Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the evaluation of carcinogenic risks to humans. Lyon, 7-14 June 1994. IARC Monogr Eval Carcinog Risks Hum: 1994; 61 1 241
89. Figueiredo C. Machado J. C. Pharoah P. et al. Helicobacter pylori and interleukin 1 genotyping: an opportunity to identify high-risk individuals for gastric carcinoma. J Natl Cancer Inst: 2002; 94 1680 1687
90. Amieva M. R. El-Omar E. M. Host-bacterial interactions in Helicobacter pylori infection. Gastroenterology: 2008; 134 306 323
91. Machado J. C. Figueiredo C. Canedo P. et al. A proinflammatory genetic profile increases the risk for chronic atrophic gastritis and gastric carcinoma. Gastroenterology: 2003; 125 364 371
92. Huang J. Q. Zheng G. F. Sumanac K. et al. Meta-analysis of the relationship between cagA seropositivity and gastric cancer. Gastroenterology: 2003; 125 1636 1644
93. Basso D. Zambon C. F. Letley D. P. et al. Clinical relevance of Helicobacter pylori cagA and vacA gene polymorphisms. Gastroenterology: 2008; 135 91 99
94. Rizzato C. Kato I. Plummer M. et al. Risk of advanced gastric precancerous lesions in Helicobacter pylori infected subjects is influenced by ABO blood group and cagA status. Int J Cancer: 2013; 133 315 322
95. Palli D. Masala G. Del Giudice G. et al. CagA+ Helicobacter pylori infection and gastric cancer risk in the EPIC-EURGAST study. Int J Cancer: 2007; 120 859 867
96. Winter J. A. Letley D. P. Cook K. W. et al. A role for the vacuolating cytotoxin, VacA, in colonization and Helicobacter pylori-induced metaplasia in the stomach. J Infect Dis: 2014; 210 954 963
97. Cover T. L. Helicobacter pylori diversity and gastric cancer risk. MBio: 2016; 7 e01869 01815
98. El-Omar E. M. Carrington M. Chow W. H. et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature: 2000; 404 398 402
99. Persson C. Canedo P. Machado J. C. et al. Polymorphisms in inflammatory response genes and their association with gastric cancer: a huge systematic review and meta-analyses. Am J Epidemiol: 2011; 173 259 270
100. Wang P. Xia H. H-X. Zhang J-Y. et al. Association of interleukin-1 gene polymorphisms with gastric cancer: A meta-analysis. Int J Cancer: 2007; 120 552 562
101. Camargo M. C. Mera R. Correa P. et al. Interleukin-1beta and interleukin-1 receptor antagonist gene polymorphisms and gastric cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev: 2006; 15 1674 1687
102. Xue H. Lin B. Ni P. et al. Interleukin-1B and interleukin-1 RN polymorphisms and gastric carcinoma risk: a meta-analysis. J Gastroenterol Hepatol: 2010; 25 1604 1617
103. Loh M. Koh K. X. Yeo B. H. et al. Meta-analysis of genetic polymorphisms and gastric cancer risk: variability in associations according to race. Eur J Cancer: 2009; 45 2562 2568
104. Hnatyszyn A. Wielgus K. Kaczmarek-Rys M. et al. Interleukin-1 gene polymorphisms in chronic gastritis patients infected with Helicobacter pylori as risk factors of gastric cancer development. Arch Immunol Ther Exp (Warsz): 2013; 61 503 512
105. Simone A. Casadei A. De Vergori E. et al. Rescue endoscopy to identify site of gastric dysplasia or carcinoma found at random biopsies. Dig Liver Dis: 2011; 43 721 725
106. Yep-Gamarra V. Diaz-Velez C. Araujo I. et al. [Usefulness of systematic chromoendoscopy with a double dye staining technique for the detection of dysplasia in patients with premalignant gastric lesions]. Gastroenterol Hepatol: 2016; 39 49 54
107. Gong E. J. Lee J. H. Jung K. et al. Characteristics of missed simultaneous gastric lesions based on double-check analysis of the endoscopic image. Clin Endosc: 2017; 50 261 269
108. Teh J. L. Tan J. R. Lau L. J. et al. Longer examination time improves detection of gastric cancer during diagnostic upper gastrointestinal endoscopy. Clin Gastroenterol Hepatol: 2015; 13 480 487.e2
109. de Vries A. C. van Grieken N. C. Looman C. W. et al. Gastric cancer risk in patients with premalignant gastric lesions: a nationwide cohort study in the Netherlands. Gastroenterology: 2008; 134 945 952
110. Song H. Ekheden I. G. Zheng Z. et al. Incidence of gastric cancer among patients with gastric precancerous lesions: observational cohort study in a low risk Western population. BMJ: 2015; 351 h3867
111. Goo J. J. Choi C. W. Kang D. H. et al. Risk factors associated with diagnostic discrepancy of gastric indefinite neoplasia: Who need en bloc resection? Surg Endosc: 2015; 29 3761 3767
112. Raftopoulos S. C. Kumarasinghe P. de Boer B. et al. Gastric intraepithelial neoplasia in a Western population. Eur J Gastroenterol Hepatol: 2012; 24 48 54
113. Fassan M. Pizzi M. Farinati F. et al. Lesions indefinite for intraepithelial neoplasia and OLGA staging for gastric atrophy. Am J Clin Pathol: 2012; 137 727 732
114. Lahner E. Esposito G. Pilozzi E. et al. Occurrence of gastric cancer and carcinoids in atrophic gastritis during prospective long-term follow up. Scand J Gastroenterol: 2015; 50 856 865
115. Shichijo S. Hirata Y. Niikura R. et al. Histologic intestinal metaplasia and endoscopic atrophy are predictors of gastric cancer development after Helicobacter pylori eradication. Gastrointest Endosc: 2016; 84 618 624
116. Reddy K. M. Chang J. I. Shi J. M. et al. Risk of gastric cancer among patients with intestinal metaplasia of the stomach in a US integrated health care system. Clin Gastroenterol Hepatol: 2016; 14 1420 1425
117. Tsai Y. C. Hsiao W. H. Yang H. B. et al. The corpus-predominant gastritis index may serve as an early marker of Helicobacter pylori-infected patients at risk of gastric cancer. Aliment Pharmacol Ther: 2013; 37 969 978
118. Zhou Y. Li H. Y. Zhang J. J. et al. Operative link on gastritis assessment stage is an appropriate predictor of early gastric cancer. World J Gastroenterol: 2016; 22 3670 3678
119. Masuyama H. Yoshitake N. Sasai T. et al. Relationship between the degree of endoscopic atrophy of the gastric mucosa and carcinogenic risk. Digestion: 2015; 91 30 36
120. Cho S. J. Choi I. J. Kook M. C. et al. Staging of intestinal- and diffuse-type gastric cancers with the OLGA and OLGIM staging systems. Aliment Pharmacol Ther: 2013; 38 1292 1302
121. Kodama M. Murakami K. Okimoto T. et al. Histological characteristics of gastric mucosa prior to Helicobacter pylori eradication may predict gastric cancer. Scand J Gastroenterol: 2013; 48 1249 1256
122. Marques-Silva L. Areia M. Elvas L. et al. Prevalence of gastric precancerous conditions: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol: 2014; 26 378 387
123. Gonzalez C. A. Sanz-Anquela J. M. Companioni O. et al. Incomplete type of intestinal metaplasia has the highest risk to progress to gastric cancer: results of the Spanish follow-up multicenter study. J Gastroenterol Hepatol: 2016; 31 953 958
124. Gonzalez C. A. Sanz-Anquela J. M. Gisbert J. P. et al. Utility of subtyping intestinal metaplasia as marker of gastric cancer risk. A review of the evidence. Int J Cancer: 2013; 133 1023 1032
125. Conchillo J. M. Houben G. de Bruine A. et al. Is type III intestinal metaplasia an obligatory precancerous lesion in intestinal-type gastric carcinoma? Eur J Cancer Prev: 2001; 10 307 312
126. Matsukura N. Onda M. Tokunaga A. et al. Mucosal IgA antibody against Helicobacter pylori in chronic gastritis and intestinal metaplasia detected by the Tes-Tape method in resection specimens after gastrectomy for gastric cancer. Cancer: 1995; 75 1472 1477
127. Silva S. Filipe M. I. Intestinal metaplasia and its variants in the gastric mucosa of Portuguese subjects: a comparative analysis of biopsy and gastrectomy material. Hum Pathol: 1986; 17 988 995
128. Oliveira C. Pinheiro H. Figueiredo J. et al. Familial gastric cancer: genetic susceptibility, pathology, and implications for management. Lancet Oncol: 2015; 16 e60 e70
129. Yaghoobi M. Bijarchi R. Narod S. A. Family history and the risk of gastric cancer. Br J Cancer: 2010; 102 237 242
130. Safaee A. Moghimi-Dehkordi B. Fatemi S. R. et al. Family history of cancer and risk of gastric cancer in Iran. Asian Pac J Cancer Prev: 2011; 12 3117 3120
131. Rokkas T. Sechopoulos P. Pistiolas D. et al. Helicobacter pylori infection and gastric histology in first-degree relatives of gastric cancer patients: a meta-analysis. Eur J Gastroenterol Hepatol: 2010; 22 1128 1133
132. Marcos-Pinto R. Dinis-Ribeiro M. Carneiro F. et al. First-degree relatives of early-onset gastric cancer patients show a high risk for gastric cancer: phenotype and genotype profile. Virchows Arch: 2013; 463 391 399
133. Rugge M. Meggio A. Pravadelli C. et al. Gastritis staging in the endoscopic follow-up for the secondary prevention of gastric cancer: a 5-year prospective study of 1755 patients. Gut: 2019; 68 11 17
134. van der Post R. S. Vogelaar I. P. Carneiro F. et al. Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers. J Med Genet: 2015; 52 361 374
135. Murphy G. Dawsey S. M. Engels E. A. et al. Cancer risk after pernicious anemia in the US elderly population. Clin Gastroenterol Hepatol: 2015; 13 2282 2289, e2281-2284
136. Landgren A. M. Landgren O. Gridley G. et al. Autoimmune disease and subsequent risk of developing alimentary tract cancers among 4.5 million US male veterans. Cancer: 2011; 117 1163 1171
137. Hemminki K. Liu X. Ji J. et al. Autoimmune disease and subsequent digestive tract cancer by histology. Ann Oncol: 2012; 23 927 933
138. Ye W. Nyren O. Risk of cancers of the oesophagus and stomach by histology or subsite in patients hospitalised for pernicious anaemia. Gut: 2003; 52 938 941
139. Kokkola A. Sjoblom S. M. Haapiainen R. et al. The risk of gastric carcinoma and carcinoid tumours in patients with pernicious anaemia. A prospective follow-up study. Scand J Gastroenterol: 1998; 33 88 92
140. Mellemkjoer L. Gridley G. Moller H. et al. [Pernicious anemia and risk of cancer in Denmark]. Ugeskr Laeger: 1997; 159 4850 4853
141. Hsing A. W. Hansson L. E. McLaughlin J. K. et al. Pernicious anemia and subsequent cancer. A population-based cohort study. Cancer: 1993; 71 745 750
142. Armbrecht U. Stockbrugger R. W. Rode J. et al. Development of gastric dysplasia in pernicious anaemia: a clinical and endoscopic follow up study of 80 patients. Gut: 1990; 31 1105 1109
143. Brinton L. A. Gridley G. Hrubec Z. et al. Cancer risk following pernicious anaemia. Br J Cancer: 1989; 59 810 813
144. Svendsen J. H. Dahl C. Svendsen L. B. et al. Gastric cancer risk in achlorhydric patients. A long-term follow-up study. Scand J Gastroenterol: 1986; 21 16 20
145. Kuipers E. J. Pernicious anemia, atrophic gastritis, and the risk of cancer. Clin Gastroenterol Hepatol: 2015; 13 2290 2292
146. Vannella L. Lahner E. Osborn J. et al. Systematic review: gastric cancer incidence in pernicious anaemia. Aliment Pharmacol Ther: 2013; 37 375 382
147. Sjoblom S. M. Sipponen P. Jarvinen H. Gastroscopic follow up of pernicious anaemia patients. Gut: 1993; 34 28 32
148. Lahner E. Caruana P. D'Ambra G. et al. First endoscopic-histologic follow-up in patients with body-predominant atrophic gastritis: when should it be done? Gastrointest Endosc: 2001; 53 443 448
149. Sjoblom S. M. Sipponen P. Miettinen M. et al. Gastroscopic screening for gastric carcinoids and carcinoma in pernicious anemia. Endoscopy: 1988; 20 52 56
150. Chen H. N. Wang Z. Li X. et al. Helicobacter pylori eradication cannot reduce the risk of gastric cancer in patients with intestinal metaplasia and dysplasia: evidence from a meta-analysis. Gastric Cancer: 2016; 19 166 175
151. Kong Y. J. Yi H. G. Dai J. C. et al. Histological changes of gastric mucosa after Helicobacter pylori eradication: a systematic review and meta-analysis. World J Gastroenterol: 2014; 20 5903 5911
152. Rokkas T. Rokka A. Portincasa P. A systematic review and meta-analysis of the role of Helicobacter pylori eradication in preventing gastric cancer. Ann Gastroenterol: 2017; 30 414 423
153. Hwang Y. J. Kim N. Lee H. S. et al. Reversibility of atrophic gastritis and intestinal metaplasia after Helicobacter pylori eradication - a prospective study for up to 10 years. Aliment Pharmacol Ther: 2018; 47 380 390
154. Kodama M. Murakami K. Okimoto T. et al. Helicobacter pylori eradication improves gastric atrophy and intestinal metaplasia in long-term observation. Digestion: 2012; 85 126 130
155. Kodama M. Murakami K. Okimoto T. et al. Ten-year prospective follow-up of histological changes at five points on the gastric mucosa as recommended by the updated Sydney system after Helicobacter pylori eradication. J Gastroenterol: 2012; 47 394 403
156. Malfertheiner P. Megraud F. O'Morain C. A. et al. Management of Helicobacter pylori infection - the Maastricht V/Florence Consensus Report. Gut: 2017; 66 6 30
157. Maehata Y. Nakamura S. Fujisawa K. et al. Long-term effect of Helicobacter pylori eradication on the development of metachronous gastric cancer after endoscopic resection of early gastric cancer. Gastrointest Endosc: 2012; 75 39 46
158. Choi J. Kim S. G. Yoon H. et al. Eradication of Helicobacter pylori after endoscopic resection of gastric tumors does not reduce incidence of metachronous gastric carcinoma. Clin Gastroenterol Hepatol: 2014; 12 793 800 e791
159. Fukase K. Kato M. Kikuchi S. et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet: 2008; 372 392 397
160. Bae S. E. Jung H. Y. Kang J. et al. Effect of Helicobacter pylori eradication on metachronous recurrence after endoscopic resection of gastric neoplasm. Am J Gastroenterol: 2014; 109 60 67
161. Bang C. S. Baik G. H. Shin I. S. et al. Helicobacter pylori eradication for prevention of metachronous recurrence after endoscopic resection of early gastric cancer. J Korean Med Sci: 2015; 30 749 756
162. Jung D. H. Kim J. H. Chung H. S. et al. Helicobacter pylori eradication on the prevention of metachronous lesions after endoscopic resection of gastric neoplasm: a meta-analysis. PLoS One: 2015; 10 e0124725
163. Choi I. J. Kook M. C. Kim Y. I. et al. Helicobacter pylori therapy for the prevention of metachronous gastric cancer. N Engl J Med: 2018; 378 1085 1095
164. Tian W. Zhao Y. Liu S. et al. Meta-analysis on the relationship between nonsteroidal anti-inflammatory drug use and gastric cancer. Eur J Cancer Prev: 2010; 19 288 298
165. Wang W. H. Huang J. Q. Zheng G. F. et al. Non-steroidal anti-inflammatory drug use and the risk of gastric cancer: a systematic review and meta-analysis. J Natl Cancer Inst: 2003; 95 1784 1791
166. Sheu B. S. Tsai Y. C. Wu C. T. et al. Long-term celecoxib can prevent the progression of persistent gastric intestinal metaplasia after H. pylori eradication. Helicobacter: 2013; 18 117 123
167. Wong B. C. Zhang L. Ma J. L. et al. Effects of selective COX-2 inhibitor and Helicobacter pylori eradication on precancerous gastric lesions. Gut: 2012; 61 812 818
168. Huang X-Z. Chen Y. Wu J. et al. Aspirin and non-steroidal anti-inflammatory drugs use reduce gastric cancer risk: A dose-response meta-analysis. Oncotarget: 2017; 8 4781 4795
169. Kong P. Wu R. Liu X. et al. The effects of anti-inflammatory drug treatment in gastric cancer prevention: an update of a meta-analysis. J Cancer: 2016; 7 2247 2257
170. Ye X. Fu J. Yang Y. et al. Frequency-risk and duration-risk relationships between aspirin use and gastric cancer: a systematic review and meta-analysis. PLoS ONE: 2013; 8 e71522
171. Bosetti C. Rosato V. Gallus S. et al. Aspirin and cancer risk: a quantitative review to 2011. Ann Oncol: 2012; 23 1403 1415
172. Tian W. Zhao Y. Liu S. et al. Meta-analysis on the relationship between nonsteroidal anti-inflammatory drug use and gastric cancer. Eur J Cancer Prev: 2010; 19 288 298
173. Abnet C. C. Freedman N. D. Kamangar F. et al. Non-steroidal anti-inflammatory drugs and risk of gastric and oesophageal adenocarcinomas: results from a cohort study and a meta-analysis. Br J Cancer: 2009; 100 551 557
174. Han X. Jiang K. Wang B. et al. Effect of rebamipide on the premalignant progression of chronic gastritis: a randomized controlled study. Clin Drug Investig: 2015; 35 665 673
175. Kamada T. Sato M. Tokutomi T. et al. Rebamipide improves chronic inflammation in the lesser curvature of the corpus after Helicobacter pylori eradication: a multicenter study. Biomed Res Int: 2015; 2015 865146 865148
176. Tang X. D. Zhou L. Y. Zhang S. T. et al. Randomized double-blind clinical trial of Moluodan () for the treatment of chronic atrophic gastritis with dysplasia. Chin J Integr Med: 2016; 22 9 18
177. Kong P. Cai Q. Geng Q. et al. Vitamin intake reduce the risk of gastric cancer: meta-analysis and systematic review of randomized and observational studies. PLoS One: 2014; 9 e116060
178. Taylor P. R. Prevention of gastric cancer: a miss. J Natl Cancer Inst: 2007; 99 101 103
179. Bjelakovic G. Nikolova D. Gluud C. Meta-regression analyses, meta-analyses, and trial sequential analyses of the effects of supplementation with beta-carotene, vitamin A, and vitamin E singly or in different combinations on all-cause mortality: do we have evidence for lack of harm? PLoS One: 2013; 8 e74558
180. Zhou Y. Zhuang W. Hu W. et al. Consumption of large amounts of allium vegetables reduces risk for gastric cancer in a meta-analysis. Gastroenterology: 2011; 141 80 89
181. Bertuccio P. Rosato V. Andreano A. et al. Dietary patterns and gastric cancer risk: a systematic review and meta-analysis. Ann Oncol: 2013; 24 1450 1458
182. Areia M. Dinis-Ribeiro M. Rocha Goncalves F. Cost-utility analysis of endoscopic surveillance of patients with gastric premalignant conditions. Helicobacter: 2014; 19 425 436
183. Zhou H. J. Dan Y. Y. Naidoo N. et al. A cost-effectiveness analysis evaluating endoscopic surveillance for gastric cancer for populations with low to intermediate risk. PLoS One: 2013; 8 e83959
184. Wu J. T. Zhou J. Naidoo N. et al. Determining the cost-effectiveness of endoscopic surveillance for gastric cancer in patients with precancerous lesions. Asia Pac J Clin Oncol: 2016; 12 359 368
185. Areia M. Carvalho R. Cadime A. T. et al. Screening for gastric cancer and surveillance of premalignant lesions: a systematic review of cost-effectiveness studies. Helicobacter: 2013; 18 325 337
186. Chang H. S. Park E. C. Chung W. et al. Comparing endoscopy and upper gastrointestinal X-ray for gastric cancer screening in South Korea: a cost-utility analysis. Asian Pac J Cancer Prev: 2012; 13 2721 2728
187. Cho E. Kang M. H. Choi K. S. et al. Cost-effectiveness outcomes of the national gastric cancer screening program in South Korea. Asian Pac J Cancer Prev: 2013; 14 2533 2540
188. Yeh J. M. Hur C. Ward Z. et al. Gastric adenocarcinoma screening and prevention in the era of new biomarker and endoscopic technologies: a cost-effectiveness analysis. Gut: 2016; 65 563 574
189. Gupta N. Bansal A. Wani S. B. et al. Endoscopy for upper GI cancer screening in the general population: a cost-utility analysis. Gastrointest Endosc: 2011; 74 610 624 e612
190. Areia M. Spaander M. C. Kuipers E. J. et al. Endoscopic screening for gastric cancer: A cost-utility analysis for countries with an intermediate gastric cancer risk. United European Gastroenterol J: 2018; 6 192 202
191. Dumonceau J. M. Hassan C. Riphaus A. et al. European Society of Gastrointestinal Endoscopy (ESGE) Guideline Development Policy. Endoscopy: 2012; 44 626 629